JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management
Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.
Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.
The FDA has granted orphan drug designation to namodenoson for the treatment of patients with pancreatic cancer.
HLX11—a pertuzumab biosimilar—plus trastuzumab/docetaxel met the pCR end point in a phase 3 trial in early or locally advanced HER2-positive breast cancer.
Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management…
Asia Pacific Regional Council inquiries: Contact morgan.dean@asco.orgConquer Cancer EveryGrant® inquiries: Contact andrew.smith@conquer.org
Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.
Ticiana Leal, MD, discusses how tarlatamab, a bispecific T-cell engager (BiTE), leverages the aberrant expression of delta-like ligand 3 on small cell lung cancer (SCLC)…
‘The Office’ fan favorite was diagnosed with stage 1 breast cancer but is now cancer-free. Experts weigh in on her cancer journey.
Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.
In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned…
The former President has been fighting to win back his wealthiest donors, while actively courting new ones—what do they expect to get in return?